

T e

affected

FIBROMYALGIA	
primary	67 (97.1%)
secondary	2 (2.9%)
DIAGNOSIS	
new diagnosis	29 (42.0%)
previous diagnosis	40 (58.0%)
ASSOCIATED DISEASES	
Osteoarthritis (different locations)	11 (15.9%)
Anxiety-depressive syndrome	11 (15.9%)
Others	13 (18.8%)
SYMPTOMS	
Asthenia	68 (98.6%)
Sleep disturbance	54 (78.3%)
Headache	49 (71.0%)
Cognitive disturbances	48 (69.6%)
Paraesthesia	48 (69.6%)
IBS	45 (65.2%)
Dizziness	44 (63.8%)
Dyspepsia	40 (58.0%)
Tachycardia	40 (58.0%)
Restless legs	31 (44.9%)
Temporomandibular pain	31 (44.9%)
Anxiety/depressive syndrome	29 (42.0%)
Irritable bladder	28 (40.6%)
Vaginismus	13 (18.8%)

PRIOR TO
VISIT 1

Cyclobenzaprine: 14 (20.3%)

Amitriptyline hydrochloride: 3 (4.3%)

Nimesulide: 2 (2.8%)

Paracetamol: 2 (2.8%)

Sulfo-adenosyl-L-methionine: 2 (2.8%)

Tizanidine: 2 (2.8%)


Unreported: 31 (44.9%)

confirmed

significant

significant

suffering



effects

TREATMENT COMPLIANCE	
As prescribed	26 (65.0%)
Reduced dose	14 (35.0%)
No of TABLETS TAKEN DAILY	
0/1/2/3/4/unreported	2/1/13/10/14/10
Other Drugs Used During The Study	
None	30 (75.0%)
Nimesulide; duloxetine (2); oxycodone; indomethacin/caffeine/prochlorperazine; NSAIDs; cyclobenzaprine; sertraline (2); herbal remedies.	
Side Effects	
None	29 (72.5%)
Epigastric pain; severe allergic skin reaction with itchiness; nausea and dizziness; dizziness and cognitive disturbances; dizziness and itchiness; xerostomia; xerostomia and constipation; constipation; general malaise; drowsiness	

effects

Te

D]gWg]cb

first

different
infamed

confirmed

T is

fibromyalgia

effects

The
Classification

different

fibromyalgia

fibromyalgia

fibromyalgia

scientific
Ter